It’s not the right time to quit: Acumen Pharmaceuticals Inc (ABOS) Stock
Deutsche Bank raised the price target for the Acumen Pharmaceuticals Inc (NASDAQ:ABOS) stock to “a Buy”. The rating was released on December 12, 2023, according to finviz. We previously noted in another research note published on July 20, 2023 by BofA Securities that resumed the stock to a Buy with a price target of $14 […]
